+670.0%
MUU vs MRNA
+233.8%
+436.1%
-84.2%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -27.9% | -2.2% | -25.7% | -27.6% |
| 7D | -43.9% | -12.7% | -31.2% | -42.8% |
| 30D | -63.2% | -20.7% | -42.6% | -62.0% |
| 3M | -69.8% | +46.3% | -116.1% | -71.0% |
| 6M | -61.9% | +305.2% | -367.1% | -75.7% |
| YTD | +93.5% | +561.2% | -467.7% | -7.9% |
| 1Y | +271.8% | +772.1% | -500.3% | +52.1% |
| All | +670.0% | +233.8% | +436.1% | +239.8% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling